BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24811541)

  • 1. Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells.
    Han M; Vakili MR; Soleymani Abyaneh H; Molavi O; Lai R; Lavasanifar A
    Mol Pharm; 2014 Aug; 11(8):2640-9. PubMed ID: 24811541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
    Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
    Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin.
    Xiong XB; Ma Z; Lai R; Lavasanifar A
    Biomaterials; 2010 Feb; 31(4):757-68. PubMed ID: 19818492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin derivative loaded acetal-PEG-PCCL micelles for overcoming multidrug resistance in MCF-7/ADR cells.
    Zhong XC; Xu WH; Wang ZT; Guo WW; Chen JJ; Guo NN; Wang TT; Lin MT; Zhang ZT; Lu YY; Yang QY; Han M; Xu DH; Gao JQ
    Drug Dev Ind Pharm; 2019 Sep; 45(9):1556-1564. PubMed ID: 31271317
    [No Abstract]   [Full Text] [Related]  

  • 6. Mitochondria and Nucleus Dual Delivery System To Overcome DOX Resistance.
    Cui H; Huan ML; Ye WL; Liu DZ; Teng ZH; Mei QB; Zhou SY
    Mol Pharm; 2017 Mar; 14(3):746-756. PubMed ID: 28146635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
    Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
    J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231.
    Aroui S; Brahim S; De Waard M; Bréard J; Kenani A
    Cancer Lett; 2009 Nov; 285(1):28-38. PubMed ID: 19523755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
    Zeng X; Morgenstern R; Nyström AM
    Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triphenylphosphonium-conjugated glycol chitosan microspheres for mitochondria-targeted drug delivery.
    Lee YH; Park HI; Chang WS; Choi JS
    Int J Biol Macromol; 2021 Jan; 167():35-45. PubMed ID: 33227331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
    Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
    J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial delivery of doxorubicin by triphenylphosphonium-functionalized hyperbranched nanocarriers results in rapid and severe cytotoxicity.
    Theodossiou TA; Sideratou Z; Katsarou ME; Tsiourvas D
    Pharm Res; 2013 Nov; 30(11):2832-42. PubMed ID: 23921486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of Mitochondrial Cell Death and Reversal of Anticancer Drug Resistance via Nanocarriers Composed of a Triphenylphosphonium Derivative of Tocopheryl Polyethylene Glycol Succinate.
    Singh Y; Viswanadham KKDR; Pawar VK; Meher J; Jajoriya AK; Omer A; Jaiswal S; Dewangan J; Bora HK; Singh P; Rath SK; Lal J; Mishra DP; Chourasia MK
    Mol Pharm; 2019 Sep; 16(9):3744-3759. PubMed ID: 31441308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
    Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
    J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis.
    Aroui S; Brahim S; Hamelin J; De Waard M; Bréard J; Kenani A
    Apoptosis; 2009 Nov; 14(11):1352-65. PubMed ID: 19731037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zirconium phosphate nanoplatelets: a biocompatible nanomaterial for drug delivery to cancer.
    Saxena V; Diaz A; Clearfield A; Batteas JD; Hussain MD
    Nanoscale; 2013 Mar; 5(6):2328-36. PubMed ID: 23392208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery.
    Scomparin A; Salmaso S; Bersani S; Satchi-Fainaro R; Caliceti P
    Eur J Pharm Sci; 2011 Apr; 42(5):547-58. PubMed ID: 21371555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells.
    Shalviri A; Raval G; Prasad P; Chan C; Liu Q; Heerklotz H; Rauth AM; Wu XY
    Eur J Pharm Biopharm; 2012 Nov; 82(3):587-97. PubMed ID: 22995704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin conjugated functionalizable carbon dots for nucleus targeted delivery and enhanced therapeutic efficacy.
    Yang L; Wang Z; Wang J; Jiang W; Jiang X; Bai Z; He Y; Jiang J; Wang D; Yang L
    Nanoscale; 2016 Mar; 8(12):6801-9. PubMed ID: 26957191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.